Importance At present, the choice of noninvasive testing for a diagnosis of significant coronary
artery disease (CAD) is ambiguous, but nuclear myocardial perfusion imaging with single-…

Selection of the right drug for the right patient is a promising approach to increase clinical
benefit of targeted therapy with monoclonal antibodies (mAbs). Assessment of in vivo …

Background Atherosclerotic plaque characteristics may affect downstream myocardial
perfusion, as well as coronary lesion severity. Objectives This study sought to evaluate the …

Background In vitro data suggest that changes in myocardial substrate metabolism may
contribute to impaired myocardial function in diabetic cardiomyopathy (DCM). The purpose of …

PET allows for quantitative, regional myocardial perfusion imaging. The short half-lives of
the perfusion tracers currently in use limit their clinical applicability. Here, the biodistribution …

Monoclonal antibodies (mAbs) against the epidermal growth factor receptor (EGFR) are
used in the treatment of advanced colorectal cancer (mCRC). Approximately 50% of patients …

The tumor programmed death ligand 1 (PD-L1) proportion score is the current method for
selecting non–small cell lung cancer (NSCLC) patients for single-agent treatment with …

Better biomarkers are needed to predict treatment outcome in non–small cell lung cancer (NSCLC)
patients treated with anti–programmed death-1/programmed death-ligand 1 (PD-1/…

Purpose PET quantification based on standardized uptake values (SUV) is hampered by
several factors, in particular by variability in PET acquisition settings and data analysis methods…

Several FDA/EMA‐approved nanomedicines have demonstrated improved pharmacokinetics
and toxicity profiles compared to their conventional chemotherapeutic counterparts. The …